C

Cellivery Therapeutics Inc
KOSDAQ:268600

Watchlist Manager
Cellivery Therapeutics Inc
KOSDAQ:268600
Watchlist
Price: 6 680 KRW -29.91% Market Closed
Market Cap: 245B KRW
Have any thoughts about
Cellivery Therapeutics Inc?
Write Note

Cellivery Therapeutics Inc
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cellivery Therapeutics Inc
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Common Shares Outstanding
â‚©37.2m
CAGR 3-Years
2%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Common Shares Outstanding
â‚©71.2m
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Common Shares Outstanding
â‚©78.1m
CAGR 3-Years
114%
CAGR 5-Years
67%
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Common Shares Outstanding
â‚©18.8m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Common Shares Outstanding
â‚©22.1m
CAGR 3-Years
5%
CAGR 5-Years
23%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Common Shares Outstanding
â‚©28m
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
7%
No Stocks Found

Cellivery Therapeutics Inc
Glance View

Market Cap
248.4B KRW
Industry
Life Sciences Tools & Services

Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Intrinsic Value
1 694.23 KRW
Overvaluation 75%
Intrinsic Value
Price
C

See Also

What is Cellivery Therapeutics Inc's Common Shares Outstanding?
Common Shares Outstanding
37.2m KRW

Based on the financial report for Sep 30, 2024, Cellivery Therapeutics Inc's Common Shares Outstanding amounts to 37.2m KRW.

What is Cellivery Therapeutics Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
18%

Over the last year, the Common Shares Outstanding growth was 1%. The average annual Common Shares Outstanding growth rates for Cellivery Therapeutics Inc have been 2% over the past three years , 18% over the past five years .

Back to Top